Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- January’s a Frost (1963) - 2nd January 2026
- Gen Z’s extreme health pledges - 2nd January 2026
- Use weight-loss jabs responsibly in 2026 - 2nd January 2026